United Therapeutics (UTHR) CEO Rothblatt Sells $5.3M of Stock

United Therapeutics Corporation Chairperson and CEO Martine A Rothblatt sold 9,500 shares of the company on October 21, 2026, according to a Form 4 filing with the SEC.

UTHR United Therapeutics Corporation

$586.77 ▲ +18.13% year to date

1M 3M YTD

Daily close · Oct 22, 2026

Inside Martine A Rothblatt's United Therapeutics Trade

The transaction was executed at an average price of $560.08 per share, totaling approximately $5.3 million. The sale was carried out pursuant to a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Rothblatt directly held 324,443 shares of the drug manufacturer, representing an ownership change of roughly 2.84% from prior levels.

Other Institutional Activity in United Therapeutics

Avoro Capital Advisors LLC grew its holdings by 147,804 shares in the quarter ended June 30, 2026, ending with 2,777,777 shares worth about $1.62 billion. Renaissance Technologies, LLC reduced its stake by 78,271 shares, leaving it with 1,708,739 shares valued at roughly $999.3 million. Jupiter Topco LLC grew its position by 415,564 shares, a 100.0% increase to 831,129 shares worth about $486.0 million.

United Therapeutics Corporation Stock Up 5.7%

United Therapeutics closed at $563.49 on October 21, 2026, and recently traded around that same level. The stock trades above its 50-day moving average of $514.75 and sits above its 200-day moving average of $527.28. Shares trade 7.5% below their 52-week high of $609.35 and 37.7% above their 52-week low of $409.07.

Recent Earnings

United Therapeutics reported trailing-twelve-month revenue of $3.15 billion and earnings of $27.89 per share. The company posted a net profit margin of 41.6% and a return on equity of 19.3%. Its next quarterly earnings release is scheduled for October 28, 2026.

Insider Buying and Selling at United Therapeutics Corporation

Earlier in October, other company leaders completed stock transactions. EVP & General Counsel Paul A Mahon sold 8,300 shares on October 15, 2026, at an average price of $544.30 for a total of $4.5 million under a planned schedule. Martine A Rothblatt also sold 9,500 shares on October 16 for about $5.1 million, another 9,500 shares on October 19 for about $5.2 million, and 9,500 shares on October 20 for about $5.3 million.

Analysts Set New Price Targets

On September 24, 2026, Goldman Sachs initiated coverage on the stock with a Sell rating and a $321.00 price target. BTIG upgraded the stock to a Buy on October 1 with a $728.00 price target. Morgan Stanley maintained an Equal-Weight rating on October 7 while raising its price target to $566.00 from $515.00. RBC Capital maintained an Outperform rating on October 8 and lifted its price target to $708.00 from $677.00. Leerink Partners maintained an Outperform rating on October 19, raising its price target to $725.00 from $685.00. Overall, the stock carries a consensus buy recommendation from 14 analyst opinions, with a mean price target of $656.93.

About United Therapeutics

United Therapeutics Corporation develops and commercializes specialty pharmaceutical products to treat rare, chronic, and severe medical conditions, focusing heavily on pulmonary hypertension and organ manufacturing technologies. The company operates from its headquarters in Silver Spring, Maryland, employing about 1,400 people.

Bottom Line

Executive transactions under pre-scheduled plans offer a glimpse into insider liquidity management without altering the core business outlook. Investors will look to the upcoming earnings report on October 28, 2026, for fresh updates on revenue growth and product pipeline progress.